153473-94-0

153473-94-0 structure

Name: Carbazeran citrate
Chemical Name: 1-(6,7-Dimethoxy-1-phthalazinyl)-4-piperidinyl ethylcarbamate 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
CAS Number: 153473-94-0
Molecular Formula: C₂₄H₃₂N₄O₁₁
Molecular Weight: 552.531
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
Create Date: 2018-06-15 17:45:42
Modify Date: 2025-08-27 20:00:12
Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1].

Name	1-(6,7-Dimethoxy-1-phthalazinyl)-4-piperidinyl ethylcarbamate 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Synonyms	1-(6,7-Dimethoxy-1-phthalazinyl)-4-piperidinyl ethylcarbamate 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Carbamic acid, N-ethyl-, 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt)

Description	Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Metabolic Disease
Target	phosphodiesterase[1]
In Vivo	Carbazeran (10 mg/kg; p.o.) (citrate) of the unmetabolized in samples from humanized-liver mice, the mean plasma concentrations are lower than in those from control mice for 0.5~4 hours after oral administration[1]. Oral administration of carbazeran (citrate) to guinea pigs has reportedly resulted in large kinetic deuterium isotope effects on the AUC and Cmax, without a change of systemic half-life[1]. Animal Model: Mice[1] Dosage: 10 mg/kg Administration: P.o. Result: The mean plasma concentrations were lower than in those from control mice for 0.5~4 hours after oral administration.
References	[1]. Uehara S, et al. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug Metab Dispos. 2020;48(7):580-586.